Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

26% of Biotechnology Companies Need Financing - Morgan Stanley

Published 05/10/2022, 07:48 am
Updated 05/10/2022, 07:48 am
© Reuters.

© Reuters.

By Sam Boughedda

Morgan Stanley analysts said in a research note Tuesday that 26% of biotechnology companies need funding.

The firm estimates 93 companies will have one year of cash or less by the end of 2022, representing 26% of companies in Morgan Stanley's sample of 360 needing to finance at least one year of operations during 2022. "We estimate the financing needs to be ~$26B, which is lower than our analysis in March that yielded ~$36B by 110 companies," said the analysts.

"Previously, our sample size was 380 companies, and we estimated ~30% of the companies would need to finance in 2022. Year to date, ~$13B of funds have been raised by ~80 companies with a minimum funding size of $30M and including private investment in public equity (PIPEs) offerings. We believe most investors want companies to keep ~2 years of cash on the balance sheet and not to drop below one year of cash," the analysts explained.

The sector's performance in the past three months was said to be slightly below the average biotech needing funding, with the 93 stocks having an average return of +4% in the past three months, above the sector index (NASDAQ Biotech) return of -4% in the same period.

Furthermore, based on a subset of recent IPOs, Morgan Stanley estimates that "42 recent IPOs will need funding with aggregate cash requirements of $8B. Relative to the universe of 194 recent IPOs, this is slightly lower than the overall set as a proportion of the universe."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.